ABSTRACT
T HE ESTABLISHMENT of the male phenotype during embryogenesis is dependent on two hormones secreted by the fetal testes. The peptide hormone Mullerian inhibiting hormone is responsible for regression of the Mullerian ducts, and the steroid hormone testosterone mediates development of the male urogenital tract and external genitalia (reviewed in Ref. 1) . Disorders that disrupt the synthesis or action of testosterone impair male phenotypic development and cause the condition of human intersex termed male pseudohermaphroditism. Defects in androgen action are the most common of these disorders and include mutations in the androgen receptor gene and mutations in the steroid 5a-reductase 2 gene, which encodes an enzyme responsible for the conversion of testosterone to dihydrotestosterone in the urogenital tract (2). Autosomal recessive mutations have also been described that impair each of the five enzymatic reactions involved in the conversion of cholesterol to testosterone, including the side-chain cleavage reaction, 3/3-hydroxysteroid dehydrogenase (3/3HSD), 17a-hydroxylase/l7,20-lyase, and 17PHSD (3). We identified the defect in the latter disorder as the consequence of mutations in the 17PHSD-3 gene and described six different mutations in five unrelated affected individuals (three homozygotes and two compound heterozygotes) (4). 17PHSD deficiency was originally described by Saez and his colleagues (5,6); the characteristic phenotype is that of a 46,XY individual with testes and male Wolffian duct-derived urogenital structures (epididymides, vas deferentia, seminal vesicles, and ejaculatory ducts) but female external genitalia (7-9). Such individuals are usually classified as female at birth and raised as females, but at the time of expected puberty, plasma testosterone rises to levels that in some instances approximate the normal male range. As a consequence, many such individuals undergo a marked virilization during the teenage years. Two explanations have been proposed to explain the fact that the impairment of testosterone synthesis is more severe during embryogenesis than in later life, namely that testosterone can be formed in extraglandular tissues from the circulating precursor androstenedione that accumulates in the disorder (10) and that the impairment of the enzyme is incomplete, so the testis can secrete some testosterone (11).
In the present study, we characterized the mutations in 12 additional individuals/families with 17PHSD-3 deficiency and studied the functional consequences of some of the mutant enzymes expressed in reporter cells. Most of these mutations cause either single amino acid substitutions or disrupt splice acceptor sites, and all but 1 of the missense mutations characterized to date impair enzyme function completely. This latter finding is in agreement with studies in 2 of the subjects, in whom we show that negligible amounts of testosterone are secreted by the testes. We conclude that circulating testosterone in most individuals with this disorder is derived from extraglandular conversion of androstenedione to testosterone by 1 or more of the unaffected 17PHSD isoenzymes.
Subjects
and Methods
Four of the subjects/families shown in Table 1 were previously reported in detail, namely 17HSD-3-Gaza (11-141, 17HSD-3-Sao Paulo 3 (15), 17HSD-3-Syria (lo), and 17HSD-3-New York (16). Two others (17HSD-3-Dallas and 17HSD-3-Sao Paulo 1) have been described in capsule form (4). The remaining 11 subjects/families have not previously been reported.
17HSD-3-&m
Francisco 1. This girl was evaluated at University of California-San Francisco at age 15 yr. The external genitalia had been considered normal at birth, but at 7 months of age she was noted to have a mass in the right labia majora. Beginning at age 13 yr, she noted breast enlargement, deepening of the voice, and enlargement of the clitoris. The family history was uninformative, and two siblings were normal. On physical examination she had facial hirsutism, 6 X 6-cm breast tissue, a 3 X 1.5-cm clitoris, scrotalization of the labia majora, and a blind-ending vagina. The karyotype was 46,XY. Endocrine findings are summarized in Table 2 . Gonadectomy was performed; the testes measured 3 X 2 cm, and by microscopic examination the seminiferous tubules contained mostly Sertoli cells and a few germ cells. DNA was prepared from tissue blocks.
27HSD-3-5~1
Francisco 2. This girl was thought to be normal at birth, but was evaluated at age 13 yr at University of California-San Francisco because of a deepening voice, hirsutism, male musculature, and an enlarged clitoris. The family history was uninformative, and a 15-yr-old sister was normal.
Breasts were Tanner stage III, and pubic hair was Tanner stage IV. The vagina was blind-ending, and masses (3.5 X 2.5 cm) were palpable in the labia majora. 
Results

Subjects
The geographical, clinical, and genetic characteristics of the subjects studied are summarized in Table 1 ; these individuals comprise about 45% of all subjects reported to date with 17PHSD deficiency. The affected individuals are from 17 families and represent diverse ethnic groups. In all instances, except 1, the diagnosis of 17PHSD deficiency was based on characteristic clinical features, namely 46,XY males with pseudohermaphroditism, measurable or male serum testosterone levels, and elevated androstenedione levels. In 1 instance (17HSD-3-Indianapolis), an infant with ambiguous genitalia was misdiagnosed as having 5cu-reductase 2 deficiency, and the correct diagnosis was only made after molecular genetic analysis. Interestingly, only a single mutant allele was identified in the 17PHSD-3 gene in this individual; we assume that the other allele probably contains a mutation outside the coding sequence of the gene, as heterozygous males with other mutations of the gene are phenotypically and endocrinologically normal. Alternatively, the individual might be a heterozygous carrier of the mutation and have some unidentified cause of ambiguous genitalia. Of the subjects in Table 1 , all have been raised as female except for 17HSD-3-Stony Brook, who is being raised as a male, and 17HSD-3-Gaza, some of whom are raised as males and some as females (11-14).
In two subjects studied at the University of California-San Francisco, androstenedione and testosterone were measured in spermatic venous blood obtained by cannulation at the time of orchidectomy, and the levels were compared with normal spermatic vein measurements from the same laboratory (Table 2) . Androstenedione levels in spermatic venous blood were elevated 15-to 20-fold, and testosterone levels were decreased 15-to 70-fold. The testosterone to androstenedione levels in these two subjects were 0.09 and 0.03, in contrast to normal ratios of 24-32.
Mutations
The mutations in this cohort are summarized in Table 1 and Fig. 1 . Fourteen different mutations have been identified 325+4, S65L<6°Q\A~T (326~l,G+C in 12 homozygotes, 4 compound heterozygotes, and 1 presumed compound heterozygote. These mutations occur in or affect the splicing of 7 exons and consist of 1 small deletion, 3 splice site mutations, and 10 missense mutations that cause single amino acid substitutions in the protein. Three of these mutations were identified in more than 1 family. The R8OQ mutation, originally identified in homozygous form in 17HSD-3-Gaza and in heterozygous form in 17HSD-3-Sao Paula 1 (4), was found in homozygous form in 17HSD-3-Sao Paula 3. Likewise, the 655-l,G+A splice acceptor site mutation previously described in 17HSD-3-Syria (4) is present in homozygous form in 17HSD-New York, and the 325+4,A+T splice acceptor site mutation was present in homozygous form in 3 families and in heterozygous form in 2 others (Table 1 ).
Expression analysis of missense mutations
To confirm that the coding sequence mutations are deleterious, five of the missense mutations that cause single amino acid substitutions (S65L, V205E, F2081, E215D, and P282L) were introduced into expressible cDNA vectors by site-directed mutagenesis, and the enzyme activity was assessed after transfection into cultured cells by measuring the conversion of radioactive androstenedione to testosterone (Fig. 2A) . The fact that the mutant cDNAs were expressed in the transfected cells was shown by immunoblotting using an antibody directed to a specific epitope of 17PHSD-3 (Fig. 2B) . In each of the mutations studied, the substitution mutation appeared to inactivate enzyme activity almost completely ( Fig. 2A) . Thus, of the nine substitution mutations analyzed by this technique to date (4), only the R80Q mutation appears to possess residual enzyme activity when studied in this manner, namely approximately 20% of the normal activity. DISCUSSION 17/3HSD-3 deficiency is a rare autosomal recessive cause of male pseudohermaphroditism. The typical subject with this disorder is a 46,XY male who is born with a female external phenotype (but with testes located in the inguinal canals or labia majora) and who undergoes considerable virilization at the time of expected puberty associated with elevated levels of blood androstenedione and either low or normal male Expression analysis of normal and mutant 17PHSD-3 isoenzymes. cDNAs encoding the normal type 3 isoenzyme or a protein harboring the indicated amino acid substitution mutation were transfected into cultured human embryonic kidney 293 cells on day 0. On day 2, the medium was supplemented with 2 pmol/L [i4Clandro-stenedione (53 mCi/mmol), and the incubation was continued for the indicated time period. Thereafter, the medium was harvested, and the conversion of androstenedione to testosterone was monitored by thin layer chromatography (A). In B, 5-pg aliquots of total cell lysate on day 3 of the experiment were analyzed by immrmoblotting using an antipeptide antibody directed against the 17PHSD-3 isoenzyme. The protein migrates with an apparent mol wt of 30,000 and is present in all transfected cells at approximately the same levels.
levels of testosterone (7-9). [Occasional individuals have ambiguous genitalia at birth (241, and two late-onset variants of uncertain pathophysiology have been described, one manifest by gynecomastia in boys (25,261 and the other as polycystic disease in women (27j.l It has been recognized for approximately 25 yr that this disorder is the result of a defect in the final step in testosterone synthesis in the testes, namely the conversion of androstenedione to testosterone (5,6). We have shown that the molecular basis of this disorder is any of several mutations in the 17/3HSD-3 gene, a gene that appears to be expressed predominately or exclusively in testes (41. In the present report we describe 9 additional mutations in this gene to make a total of 14 different mutations in 17 subjects/families. Twelve are present in homozygous form, 4 are compound heterozygotes, and 1 is a presumed compound heterozygote.
These mutations consist of a 7-nucleotide deletion that causes a frame shift, 3 splice site abnormalities, and 10 missense mutations that cause amino acid substitutions. Three of these mutations (R8OQ, 655-1, G+ A, and 325 + 4,A-+ T) have been identified in more than 1 family; we do not know at present whether this recurrence is due to a founder effect or to recurrent new mutations.
Two characteristic features of the disorder are particularly puzzling: 1) the defect in virilization and the deficiency in testosterone synthesis are usually more complete during embryogenesis than in later life, implying that an alternate route for testosterone synthesis must be activated at the time of expected puberty; and 2) the external genitalia at birth are usually female in character, but the Wolffian duct structures (epididymides, vasa deferentia, and seminal vesicles) virilize normally, indicating that androgen must act by an alternate mechanism in these tissues in utero.
The findings in the present study provide insight into the source of circulating testosterone after the time of expected puberty in this disorder. Two theories have been proposed to explain this phenomenon. First, Akesode and his colleagues (10) concluded on the basis of studies of the metabolism of radioactive precursors in a single affected subject (17HSD-3-Syria) that testosterone is formed from circulating androstenedione by extraglandular conversion. Second, on the basis of studies of the hormone concentrations in testicular venous blood from several related subjects from the Gaza strip (VHSD-3-GazaJ E&stein et aI. 01) demonstrated that considerable amounts of testosterone can be secreted by the testes of affected members of that kindred. Using site-directed mutagenesis and transient transfection assays, we demonstrated that eight of the nine missense mutations inactivate enzyme activity almost completely. Furthermore, in two of the individuals with inactive n&sense mutations, assessment of testosterone and androstenedione levels in testicular venous blood indicated that these individuals secrete only 5% as much testosterone from the testes as normal controls. This finding is in keeping with the fact that the expressed enzyme from the subject described by Akesode et al. (10) (VI-ISD+Syria) was also inactive when transiently expressed in reporter cells (4). As the other mutations characterized to date, the frame-shift mutation and the splice acceptor site abnormalities, are predicted to preclude the formation of functional protein, we conclude that the common mechanism for testosterone synthesis (and for the resulting virilization) after the time of expected puberty in this disorder is by extraglandular formation. It is of interest in this regard that in the one exception to this generalization (subjects from the Gaza family who carry the RSOQ mutation), not only was testosterone secreted by the testes (10, but in addition, the expression of the reconstructed DNA containing this mutation caused the formation of an enzyme with about 15-20% of normal enzyme activity at high substrate concentrations (4).
Whether the enzyme responsible for extraglandular conversion of androstenedione to testosterone is isoenzyme 1 or 2 or some other 17PHSD enzyme is, at present, unclear, nor is it understood why this process seems to be more efficient in later life than during embryogenesis. The enhancement of testosterone synthesis at the time of expected puberty may be the consequence of the increased output of androstenedione by the testes after the pubertal surge of LH secretion and, hence, the availability of more substrate for testosterone synthesis in extraglandular sites by other isoenzymes.
The present studies also leave unexplained the virilization of the Wolffian ducts in these subjects during fetal life. At the simplistic level, virilization in the absence of circulating testosterone could be due to the presence in the tissue of an embryonic receptor mechanism that lacks the specificity of the mature androgen receptor or to the presence in the tissue of an alternate mechanism for the conversion of circulating androstenedione. So far as can be ascertained, the embryonic Wolffian duct androgen receptor is identical to the receptor in other tissues (28), and we, therefore, conclude that this tissue must contain an alternate pathway for testosterone formation, possibly the same 17PHSD responsible for extraglandular testosterone formation in later life. The mechanism by which the Wolffian ducts virilize in this disorder is now under scrutiny.
Extraglandular testosterone formation may also be responsible for one other unexpected finding in the present study. Namely, 1 of the 16 homozygotes/compound heterozygotes in the present study (VHSD-3-Stony Brook) had clear-cut ambiguous genitalia at the time of birth, implying considerable testosterone formation during embryogenesis. It was, therefore, unexpected that when the reconstructed DNA containing this mutation (F2081) was expressed in reporter cells, the mutant 17PHSD was totally inactive. It is possible that there is considerable genetic variability among individuals in the capacity for extraglandular testosterone formation.
